» Articles » PMID: 36527449

Prevalence of Familial Hypercholesterolemia in Patients with Confirmed Premature Coronary Artery Disease in Ranchi, Jharkhand

Overview
Journal Egypt Heart J
Publisher Springer
Date 2022 Dec 17
PMID 36527449
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Familial hypercholesterolemia (FH) is an under-diagnosed autosomal co-dominant genetic disorder characterized by very high plasma levels of low-density lipoprotein cholesterol (LDL-C), premature coronary artery disease (CAD) with arcus cornealis, and xanthomas. Among patients with CAD, the frequency of FH is significantly higher than that of the general population, but little data are available in India in this regard. This study aimed to assess the prevalence of FH in patients with premature coronary artery disease for the first time in the Jharkhand population.

Results: The study was conducted on 200 premature CAD patients at RIMS hospital, Ranchi, from January 2020 to June 2021 with CAG-confirmed acute coronary syndrome. The study, without taking the aid of genetic profiling of the patients and using the Dutch Lipid Clinic Network Criteria, revealed quite a high (23.5%) prevalence of potential FH in patients with premature CAD apart from the conventional risk factors. Mean LDL-C levels among patients with definite, probable, possible, and no FH were recorded as 250.39, 184.32, 136.11, and 108.09 mg/dl, respectively. Arcus cornealis was seen in 55.31% of patients with potential FH, 90% in definite FH, and 44.40% with probable FH. Patients with potential FH were more likely to be younger (age < 40 years) males, having a history of CAD and a family history of premature CAD as compared to patients without FH.

Conclusions: There was no previous report of large studies on FH or its epidemiology and its natural history from India. The present study is the first one to show a high prevalence of potential FH in premature CAD (about 23.5%). This preliminary study revealed that the prevalence of FH in patients with premature CAD who came to the tertiary care hospital of Ranchi, Jharkhand, was high, apart from the conventional risk factors.

Citing Articles

Clinical and angiographic characteristics of patients with familial hypercholesterolemia presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Elmaghraby K, Abdel-Galeel A, Osman A, Hasan-Ali H, Abdelmegid M Sci Rep. 2024; 14(1):27098.

PMID: 39511296 PMC: 11543695. DOI: 10.1038/s41598-024-77656-4.


Prevalence of genetically diagnosed familial hypercholesterolemia in Vietnamese patients with premature acute myocardial infarction.

Minh Nguyen K, Hoang S Medicine (Baltimore). 2024; 103(39):e39939.

PMID: 39331889 PMC: 11441875. DOI: 10.1097/MD.0000000000039939.


The Effects of Red Palm Oil, Koja Bay Leaves, and Passion Fruit Seeds Formulation on Antioxidant Activity, Antihyperlipidemia, BDNF, and Lipase Enzyme Activity on Sprague-Dawley Rats.

Sari D, Ibrahim N, Herlina N, Arrasyid N, Dharmajaya R, Rachmawati M J Exp Pharmacol. 2024; 16:271-284.

PMID: 39262571 PMC: 11389710. DOI: 10.2147/JEP.S466494.


Applications of machine learning in familial hypercholesterolemia.

Luo R, Wang J, Hu L, Fu Q, Zhang S, Jiang L Front Cardiovasc Med. 2023; 10:1237258.

PMID: 37823179 PMC: 10562581. DOI: 10.3389/fcvm.2023.1237258.

References
1.
Gaudet D, Vohl M, Julien P, Tremblay G, Perron P, Gagne C . Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. Am J Cardiol. 1998; 82(3):299-305. DOI: 10.1016/s0002-9149(98)00328-2. View

2.
Van Loon J, de Maat M, Deckers J, van Domburg R, Leebeek F . Prognostic markers in young patients with premature coronary heart disease. Atherosclerosis. 2012; 224(1):213-7. DOI: 10.1016/j.atherosclerosis.2012.06.067. View

3.
Austin M, Hutter C, Zimmern R, Humphries S . Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004; 160(5):407-20. DOI: 10.1093/aje/kwh236. View

4.
Lui D, Lee A, Tan K . Management of Familial Hypercholesterolemia: Current Status and Future Perspectives. J Endocr Soc. 2021; 5(1):bvaa122. PMC: 8059332. DOI: 10.1210/jendso/bvaa122. View

5.
Khera A, Hegele R . What Is Familial Hypercholesterolemia, and Why Does It Matter?. Circulation. 2020; 141(22):1760-1763. PMC: 7299543. DOI: 10.1161/CIRCULATIONAHA.120.046961. View